Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance

Retinoid therapy is widely employed in clinical oncology to differentiate malignant cells into their more benign counterparts. However, certain high-risk cohorts, such as patients with MYCN-amplified neuroblastoma, are innately resistant to retinoid therapy.